Literature DB >> 17622494

A young man with persistent eosinophilia.

E Messa1, D Cilloni, G Saglio.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17622494     DOI： 10.1007/s11739-007-0030-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  24 in total

Review 1.  Systemic lupus erythematosus, eosinophilia and Löffler's endocarditis. An unusual association.

Authors:  M Thomeer; P Moerman; R Westhovens; A Van den Eeckhout; J Dequeker; M Demedts
Journal:  Eur Respir J       Date:  1999-04       Impact factor: 16.671

Review 2.  The clinical spectrum of pulmonary aspergillosis.

Authors:  Ayman O Soubani; Pranatharthi H Chandrasekar
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

3.  Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.

Authors:  A Sefcick; D Sowter; E DasGupta; N H Russell; J L Byrne
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

4.  Clonal nature of hypereosinophilic syndrome.

Authors:  M Luppi; R Marasca; M Morselli; P Barozzi; G Torelli
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

5.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  Treatment of hypereosinophilic syndrome with imatinib mesilate.

Authors:  Gerald J Gleich; Kristin M Leiferman; Animesh Pardanani; Ayalew Tefferi; Joseph H Butterfield
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Authors:  A Pardanani; R P Ketterling; C-Y Li; M M Patnaik; A P Wolanskyj; M A Elliott; J K Camoriano; J H Butterfield; G W Dewald; A Tefferi
Journal:  Leuk Res       Date:  2006-01-06       Impact factor: 3.156

8.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

9.  Clonality of isolated eosinophils in the hypereosinophilic syndrome.

Authors:  H W Chang; K H Leong; D R Koh; S H Lee
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

10.  A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report.

Authors:  A Kawasaki; Y Mizushima; S Matsui; K Hoshino; S Yano; M Kitagawa
Journal:  Tumori       Date:  1991-12-31
View more
  2 in total

1.  Selective IgA deficiency mimicking Churg-Strauss syndrome and hypereosinophilic syndrome: a case report.

Authors:  Noriyuki Takahashi; Takeshi Kondo; Mamiko Fukuta; Ayumu Takemoto; Yuichiro Takami; Motoki Sato; Takafumi Ando; Naozumi Hashimoto; Tomio Suzuki; Juichi Sato; Masahiro Yamamura; Nobutaro Ban
Journal:  Nagoya J Med Sci       Date:  2013-02       Impact factor: 1.131

Review 2.  Primary immunodeficiencies associated with eosinophilia.

Authors:  Behdad Navabi; Julia Elizabeth Mainwaring Upton
Journal:  Allergy Asthma Clin Immunol       Date:  2016-05-24       Impact factor: 3.406
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.